p.91 抽出テキスト

September 25, 2018 Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 e362

CLINICAL STATEMENTS AND GUIDELINES S5.1.5.2-22.	 Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug

use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J. 2001;142:520–9. S5.1.5.2-23.	 Farre J, Romero J, Rubio JM, et al. Amiodarone and “primary” prevention of sudden death: critical review of a decade of clinical trials. Am J Cardiol. 1999;83:55D–63D. S5.1.5.2-24.	 Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37. S5.1.5.2-25.	 Thomas KL, Al-Khatib SM, Lokhnygina Y, et al. Amiodarone use after acute myocardial infarction complicated by heart failure and/ or left ventricular dysfunction may be associated with excess mortality. Am Heart J. 2008;155:87–93. S5.1.5.2-26.	 Claro JC, Candia R, Rada G, et al. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database Syst. Rev. 2015;12:CD008093. S5.1.5.2-27.	 Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871–8. S5.1.5.2-28.	 Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346:884–90. S5.1.5.2-29.	 Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol. 1996;27:67–75. S5.1.5.2-30.	 Epstein AE, Olshansky B, Naccarelli GV, et al. Practical management guide for clinicians who treat patients with amiodarone. Am J Med. 2016;129:468–75. S5.1.5.2-31.	 Kuhlkamp V, Mewis C, Mermi J, et al. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol. 1999;33:46–52. S5.1.5.2-32.	 Waldo AL, Camm AJ, deRuyter H, et al. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am J Cardiol. 1995;75:1023–7. S5.1.5.2-33.	 Page RL. Effects of antiarrhythmic medication on implantable cardioverter-defibrillator function. Am J Cardiol. 2000;85:1481–5. S5.1.5.2-34.	 Buxton AE, Marchlinski FE, Doherty JU, et al. Hazards of intravenous verapamil for sustained ventricular tachycardia. Am J Cardiol. 1987;59:1107–10. S5.1.5.2-35.	 Belhassen BHorowitz LN. Use of intravenous verapamil for ventricular tachycardia. Am J Cardiol. 1984;54:1131–3. S5.1.5.2-36.	 Griffith MJ, Garratt CJ, Rowland E, et al. Effects of intravenous adenosine on verapamil-sensitive “idiopathic” ventricular tachycardia. Am J Cardiol. 1994;73:759–64. S5.1.5.2-37.	 Gill JS, Blaszyk K, Ward DE, et al. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J. 1993;126:1126–33. S5.1.5.2-38.	 Badhwar N, Scheinman MM. Idiopathic ventricular tachycardia: diagnosis and management. Curr Probl Cardiol. 2007;32:7–43. S5.1.5.2-39.	 Gill JS, Ward DE, Camm AJ. Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. Pacing Clin Electrophysiol. 1992;15:2122–6. S5.1.5.2-40.	 Investigators in the Magnesium in Coronaries (MAGIC) Trial. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet. 2002;360:1189–96. S5.1.5.2-41.	 Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311–5. S5.1.5.2-42.	 Kafka H, Langevin L, Armstrong PW. Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Arch Intern Med. 1987;147:465–9. S5.1.5.2-43.	 Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation. 1998;98:1928–36. S5.1.5.2-44.	 Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77:392–7. S5.1.5.2-45.	 Leier CV, Dei CL, Metra M. Clinical relevance and management

of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J. 1994;128:564–74. S5.1.5.2-46.	 Cohn JN, Kowey PR, Whelton PK, et al. New guidelines for potas-

sium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med. 2000;160:2429–36. S5.1.5.2-47.	 Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004;43:155–61. S5.1.5.2-48.	 Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307:157–64. S5.1.5.2-49.	 Leaf A, Kang JX, Xiao YF, et al. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation. 2003;107:2646–52. S5.1.5.2-50.	 Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296:1885–99. S5.1.5.2-51.	 Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897–903. S5.1.5.2-52.	 Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–26. S5.1.5.2-53.	 Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152–9. S5.1.5.2-54.	 Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr. 2003;57:193–200. S5.1.5.2-55.	 Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273. S5.1.5.2-56.	 Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309–18. S5.1.5.2-57.	 LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–6. S5.1.5.2-58.	 Buber J, Goldenberg I, Moss AJ, et al. Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with nonischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2012;60:749–55. S5.1.5.2-. 59 Investigators in TAvIDAA comparison of antiarrhythmicdrug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83. S5.1.5.2-60.	 Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. 2003;42:81–7. S5.1.5.2-61.	 Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007;153:573–8. S5.1.5.2-62.	 Goldberger JJ, Subacius H, Schaechter A, et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1228–33. S5.1.5.2-63.	 Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61. S5.1.5.2-64.	 Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvas-

tatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231–9.

5.2 Preventing SCD With HF Medications

S5.2-1.	 Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA

focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management

Downloaded from http://ahajournals.org by on October 7, 2026